[an error occurred while processing this directive] | [an error occurred while processing this directive]
Correlation of short diameter of residual lymph nodes with efficacy and prognosis in esophageal squamous cell carcinoma patients undergoing chemoradiotherapy and establishment of a Nomogram model
Ma Yuanyuan, Xia Jianhong, Li Hongliang, Su Xinyu, Zhou Liqing
Department of Radiation Oncology, Affiliated Huai'an Hospital of Xuzhou Medical University, Second People's Hospital of Huai'an, Huai'an 223000, China
AbstractObjective To analyze the correlation of the short diameter of residual lymph nodes with the efficacy and prognosis of patients with esophageal squamous cell carcinoma (ESCC) undergoing chemoradiotherapy (CRT), and establish a Nomogram prediction model to predict the prognosis of ESCC patients. Methods Clinical data of 143 ESCC patients who underwent CRT in Second People's Hospital of Huai'an from August 2018 to September 2020 were collected. The survival analysis was conducted with Kaplan-Meier method, log-rank test and univariate prognostic analysis. Multivariate prognostic analysis was performed with Cox models. Finally, a Nomogram prediction model was established to predict the 1-year and 2-year progression-free survival (PFS) of patients, and the C-index, AUC, and calibration curve were used to evaluate the performance of the model. Results Logistic regression analysis results showed that differentiation, TNM staging, PG-SGA scores before and after radiotherapy (RT) and short diameter of residual lymph nodes were the independent predictors of clinical efficacy of ESCC patients treated with CRT. Cox regression analysis demonstrated that differentiation, TNM staging, PG-SGA scores before and after RT and short diameter of residual lymph nodes were the independent prognostic predictors of ESCC patients undergoing CRT. Conclusions The short diameter of residual lymph nodes is significantly correlated with the efficacy and prognosis of ESCC patients undergoing CRT. The Nomogram prediction model established after comprehensive clinical baseline characteristics is a practical and reliable tool for predicting clinical prognosis of ESCC patients.
Ma Yuanyuan,Xia Jianhong,Li Hongliang et al. Correlation of short diameter of residual lymph nodes with efficacy and prognosis in esophageal squamous cell carcinoma patients undergoing chemoradiotherapy and establishment of a Nomogram model[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1244-1249.
Ma Yuanyuan,Xia Jianhong,Li Hongliang et al. Correlation of short diameter of residual lymph nodes with efficacy and prognosis in esophageal squamous cell carcinoma patients undergoing chemoradiotherapy and establishment of a Nomogram model[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1244-1249.
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI:10.3322/caac.21492. [2] 中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会,中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南(2020年版)[J]. 国际肿瘤学杂志,2020, 47(11):641-655. DOI:10.3760/cma.j.cn371439-20201015-00095. Chinese Association for Therapeutic Radiation Oncologists. Guidelines for radiotherapy of esophageal cancer in China (2020 version)[J]. J Int Oncol, 2020, 47(11):641-655. DOI:10.3760/cma.j.cn371439-20201015-00095. [3] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. DOI:10.1016/j.ejca.2008.10.026. [4] Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer[J]. Lancet, 2017, 390(10110):2383-2396. DOI:10.1016/S0140-6736(17)31462-9. [5] Zhang H, Liang H, Gao Y, et al. Metastatic lymph node ratio demonstrates better prognostic stratification than pN staging in patients with esophageal squamous cell carcinoma after esophagectomy[J]. Sci Rep, 2016, 6:38804. DOI:10.1038/srep38804. [6] Hölscher AH, Bollschweiler E, Schröder W, et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer[J]. Ann Surg, 2011, 254(5):802-807;discussion 807-808. DOI:10.1097/SLA.0b013e318 2369128. [7] Shao Y, Geng Y, Gu W, et al. Assessment of lymph node ratio to replace the pN categories system of classification of the TNM system in esophageal squamous cell carcinoma[J]. J Thorac Oncol, 2016, 11(10):1774-1784. DOI:10.1016/j.jtho.2016.06.019. [8] Chen JN, Liu Z, Wang ZJ, et al. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer[J]. World J Gastroenterol, 2020, 26(21):2877-2888. DOI:10.3748/wjg.v26.i21.2877. [9] Shi J, Lian CL, Chi F, et al. Prognostic and predictive value of the American Joint Committee on Cancer pathological prognostic staging system in nodal micrometastatic breast cancer[J]. Frontiers in oncology, 2020, 10:570175. DOI:10.3389/fonc.2020.570175. [10] 任雪姣,王澜,陈丽滢,等. 食管癌钡餐造影结合CT近期疗效评价标准的临床应用研究[J]. 中华放射肿瘤学杂志,2018, 27(5):449-454. DOI:10.3760/cma.j.issn.1004-4221.2018.05.004. Ren XJ, Wang L, Chen LY, et al. Clinical application of barium radiography and computed tomography-based short-term out-come evaluation criteria in esophageal cancer[J]. Chin J Radiat Oncol, 2018, 27(5):449-454. DOI:10.3760/cma.j.issn.1004-4221.2018.05.004. [11] Rice TW, Gress DM, Patil DT, et al. Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017, 67(4):304-317. DOI:10.3322/caac.21399. [12] Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer[J]. Eur J Clin Nutr, 2002, 56(8):779-785. DOI:10.1038/sj.ejcn.1601412. [13] Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. JAMA Oncol, 2015, 1(8):1051-1059. DOI:10.1001/jamaoncol.2015.2639. [14] Sugawara K, Yamashita H, Uemura Y, et al. Numeric pathologic lymph node classification shows prognostic superiority to topographic pN classification in esophageal squamous cell carcinoma[J]. Surgery, 2017, 162(4):846-856. DOI:10.1016/j.surg.2017.06.013. [15] Min BH, Yang JW, Min YW, et al. Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma[J]. J Gastroenterol Hepatol, 2020, 35(6):1009-1015. DOI:10.1111/jgh.14915. [16] Hagi T, Makino T, Yamasaki M, et al. Pathological regression of lymph nodes better predicts long-term survival in esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery[J]. Ann Surg, 2020. DOI:10.1097/SLA.0000000000004238. [17] Wang ZL, Chen Y, Li XT, et al. Potential of baseline computed tomography to predict long-term survival of patients with locally advanced esophageal cancer treated with preoperative chemotherapy:a retrospective cohort study[J]. Medicine (Baltimore), 2016, 95(18):e3583. DOI:10.1097/MD.0000000000003583. [18] Urakawa S, Makino T, Yamasaki M, et al. Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer[J]. Ann Surg, 2021, 273(6):1141-1149. DOI:10.1097/SLA.0000000000003445. [19] Guo R, Su Y, Si J, et al. A nomogram for predicting axillary pathologic complete response in hormone receptor-positive breast cancer with cytologically proven axillary lymph node metastases[J]. Cancer, 2020, 126suppl 16:3819-3829. DOI:10.1002/cncr.32830. [20] Mo S, Cai X, Zhou Z, et al. Nomograms for predicting specific distant metastatic sites and overall survival of colorectal cancer patients:a large population-based real-world study[J]. Clin Transl Med, 2020, 10(1):169-181. DOI:10.1002/ctm2.20. [21] Long J, Zhang L, Wan X, et al. A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma[J]. J Cell Mol Med, 2018, 22(12):5928-5938. DOI:10.1111/jcmm.13863. [22] Dong J, Zhang W, Zhang T, et al. Baseline nutritional status could be a predictor for radiation esophagitis in esophageal cancer patients undergoing radiotherapy[J]. Ann Transl Med, 2020, 8(18):1148. DOI:10.21037/atm-20-4078. [23] Marshalla KM, Loeligera J, Nolte L, et al. Prevalence of malnutrition and impact on clinical outcomes in cancer Q1services:a comparison of two time points[J]. Clinical Nutrition, 2018, 13(6):612-632. DOI:10.1177/1747493018778713. [24] Yang L, Gao J, Zhou Y, et al. Effect of oral nutritional supplements on patients with esophageal cancer during radiotherapy[J]. Cancer Biother Radiopharm, 2020. DOI:10.1089/cbr.2020.38 88. [25] Xu H, Lin M, Hu Y, et al. Lymphopenia during definitive chemoradiotherapy in esophageal squamous cell carcinoma:association with dosimetric parameters and patient outcomes[J]. Oncologist, 2021, 26(3):e425-e434. DOI:10.1002/onco.13533. [26] Arigami T, Uchikado Y, Omoto I, et al. Primary tumor score based on tumor depth and length predicts prognosis in esophageal squamous cell carcinoma[J]. Anticancer Res, 2018, 38(9):5447-5452. DOI:10.21873/anticanres.12876. [27] Wang BY, Goan YG, Hsu PK, et al. Tumor length as a prognostic factor in esophageal squamous cell carcinoma[J]. Ann Thorac Surg, 2011, 91(3):887-893. DOI:10.1016/j.athoracsur.2010.11.011.
2021, Vol. 30 
